Speaking during the release of their latest financial results Monday, Özlem Türeci, chief medical officer at BioNTech, said a third dose should likely be given six to 12 months after an initial round of vaccination. But BioNTech doesn’t see the need to retool the vaccine to target the highly infectious Delta variant. That’s not to say future variants won’t change this stance, with the CEO of BioNTech, Uğur Şahin, adding that it was “quite possible that in the next six to 12 months, further variants emerge that would require adaptation of the vaccine.”